Thiazolidinediones: effects on insulin resistance and the cardiovascular system.
about
PPAR-γ agonists and their effects on IGF-I receptor signaling: Implications for cancerEnhancement of mesenteric artery contraction to 5-HT depends on Rho kinase and Src kinase pathways in the ob/ob mouse model of type 2 diabetesSitagliptin added to treatment with ongoing pioglitazone for up to 52 weeks improves glycemic control in Japanese patients with type 2 diabetes.Minireview: Pathophysiological roles of the TR4 nuclear receptor: lessons learned from mice lacking TR4Cellular and pharmacological selectivity of the peroxisome proliferator-activated receptor-beta/delta antagonist GSK3787.Adiponectin prevents diabetic premature senescence of endothelial progenitor cells and promotes endothelial repair by suppressing the p38 MAP kinase/p16INK4A signaling pathway.Short communication: PPAR gamma mediates a direct antiangiogenic effect of omega 3-PUFAs in proliferative retinopathyEffects of thiazolidinediones on polycystic ovary syndrome: a meta-analysis of randomized placebo-controlled trials.Pioglitazone attenuates prostatic enlargement in diet-induced insulin-resistant rats by altering lipid distribution and hyperinsulinaemia.The complexities of obesity and diabetes with the development and progression of pancreatic cancer.Obesity and breast cancer: the roles of peroxisome proliferator-activated receptor-γ and plasminogen activator inhibitor-1Effects of rosiglitazone on the configuration of action potentials and ion currents in canine ventricular cells.In vivo and in vitro evidence that PPARγ ligands are antagonists of leptin signaling in breast cancerDrospirenone/ethinyl estradiol versus rosiglitazone treatment in overweight adolescents with polycystic ovary syndrome: comparison of metabolic, hormonal, and cardiovascular risk factors.The Differential Effects of Anti-Diabetic Thiazolidinedione on Prostate Cancer Progression Are Linked to the TR4 Nuclear Receptor Expression Status.ERK5 activation in macrophages promotes efferocytosis and inhibits atherosclerosis.PPARG, AGTR1, CXCL16 and LGALS2 polymorphisms are correlated with the risk for coronary heart disease.Pioglitazone treatment decreases follicular fluid levels of tumor necrosis factor-α and interleukin-6 in patients with polycystic ovary syndromeEffect of Rosiglitazone and Insulin Combination Therapy on Inflammation Parameters and Adipocytokine Levels in Patients with Type 1 DMResolvin D1 and resolvin D2 govern local inflammatory tone in obese fatIn Vitro and In Vivo Characterizations of Chiglitazar, a Newly Identified PPAR Pan-Agonist.The Role of PPAR-gamma and Its Interaction with COX-2 in Pancreatic Cancer.Metabolic syndrome in Iranian youths: a population-based study on junior and high schools students in rural and urban areas.Phytochemicals Mediate the Expression and Activity of OCTN2 as Activators of the PPARγ/RXRα Pathway.The effect of exercise training combined with PPARγ agonist on skeletal muscle glucose uptake and insulin sensitivity in induced diabetic obese Zucker rats.Role of peroxisome proliferator-activated receptor gamma and its ligands in the treatment of hematological malignanciesMolecular mechanisms involved in obesity-associated insulin resistance: therapeutical approach.Peroxisome proliferator-activated receptors and atherosclerosis.Tumor necrosis factor-α-induced inflammatory responses in cattle.Submaximal PPARγ activation and endothelial dysfunction: new perspectives for the management of cardiovascular disorders.Rapid and contrasting effects of rosiglitazone on transient receptor potential TRPM3 and TRPC5 channelsPPARγ activator, rosiglitazone: Is it beneficial or harmful to the cardiovascular system?PPAR-γ agonist attenuates inflammation in aortic aneurysm patients.The use of Cox-2 and PPARγ signaling in anti-cancer therapies.Pioglitazone and the secondary prevention of cardiovascular disease. A meta-analysis of randomized-controlled trials.Thiazolidinediones inhibit hepatocarcinogenesis in hepatitis B virus-transgenic mice by peroxisome proliferator-activated receptor gamma-independent regulation of nucleophosmin.Modulation of metabolic and cardiac dysfunctions by insulin sensitizers and angiotensin receptor blocker in rat model of type 2 diabetes mellitus.Palmitate-induced insulin resistance is attenuated by Pioglitazone and EGCG through reducing the gluconeogenic key enzymes expression in HepG2 cells.Peroxisome proliferator-activated receptor γ agonists attenuate hyperglycaemia-induced hyaluronan secretion in vascular smooth muscle cells by inhibiting PKCβ2.An MG53-IRS1-interaction disruptor ameliorates insulin resistance.
P2860
Q21328702-2A89B86F-5252-4C9D-8D5B-2B00D650AF78Q28749389-A62E1162-72F9-4704-B94D-18FA4E06F7CFQ33603551-C26E5D68-5842-4B01-B2C2-D43EAE19AD7CQ33701419-434746C5-9150-4659-9102-C5C366E8D2E8Q34128015-22E5A3AC-0676-433A-87A4-7A9D28F113FCQ34237779-C80E8E9C-D378-46E5-8C32-E7F166D32017Q34287296-13AEC267-8314-4415-B1D3-8D6E73C4DA1DQ34397685-4B1DBE10-9FF9-4C12-BAEF-588BDEDD63F6Q34442391-83639352-7926-45AC-A9D7-5F11320BD95AQ34669361-5E45A4BD-6851-4656-BFB7-D47E6432FA8AQ34996841-80BDAC81-D0BC-480B-9F4E-123CF087E159Q35005663-4A5007C7-602E-43A4-A1BC-3EA02C5BD113Q35168034-13D4282B-6FEE-45C6-90D6-47A30B2D439DQ35468539-59676FDC-D59B-419D-8427-3D4388A79ABFQ35555401-B1AE5F26-10B8-447E-9D28-F6CC6DEBD1D1Q35629054-3C670969-7CD0-4DB3-9223-46356F9BE94CQ35632330-D63CF59F-A57F-4134-82AF-938AA38FC734Q35767762-84569834-082C-4B5C-97F7-99FA43371147Q35932449-CBEE4E82-6AD1-44AA-8C13-BEF9E06A0431Q36179560-CDF6C448-E005-4457-808B-C27445C48415Q36363679-340DFEAD-42C0-4313-8F4E-41EA5B46D2E0Q36742740-6C5274AD-94D7-454D-BEF0-389849C9AB56Q36931481-F7DF2849-7A55-479A-AD5E-114CE264BCD2Q37048770-7DEBF97D-838A-40A0-B84A-7A15D3B846A4Q37160834-426F88EA-1A11-4741-8C2D-48C0EAE7258EQ37182794-3011EA89-54AE-4BA7-AEAE-43C5C76B63B6Q37578545-2CC3E879-01AE-40FC-B015-8250FEE26F1FQ37861955-18A4B829-89E8-4E08-BBD1-C8B3DEDD377AQ37906773-980D810D-A73A-48ED-9000-6D030F987931Q37992099-7A6E24BA-AC05-4EB3-ADF4-A19AF31DE741Q39575691-51FF6864-D2F4-408D-A7A6-9404398B93ACQ39740098-71CEEFC5-2FF1-40F3-BD26-0A742E0D165EQ40693751-2D1B35A1-2763-4463-BE91-D914D0950280Q42116284-2DF2264D-2188-410F-9C61-06902C94BEC7Q42379243-D97B620D-B99F-4DC2-BA7F-66679985CA0DQ45374016-B674692C-361E-4189-9215-0B4BD1ACD77CQ46361420-07EFC05A-390F-4288-BE60-CEF7F1DE4FFDQ49837836-4A7C3DCF-F701-4243-8CBE-0237E682BB4FQ54444900-5409DDD8-8EE1-4911-8A7E-FC2BD4135947Q55400599-71567247-F7EF-42B7-A434-A3519DBBDC7B
P2860
Thiazolidinediones: effects on insulin resistance and the cardiovascular system.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Thiazolidinediones: effects on insulin resistance and the cardiovascular system.
@ast
Thiazolidinediones: effects on insulin resistance and the cardiovascular system.
@en
type
label
Thiazolidinediones: effects on insulin resistance and the cardiovascular system.
@ast
Thiazolidinediones: effects on insulin resistance and the cardiovascular system.
@en
prefLabel
Thiazolidinediones: effects on insulin resistance and the cardiovascular system.
@ast
Thiazolidinediones: effects on insulin resistance and the cardiovascular system.
@en
P2093
P2860
P356
P1476
Thiazolidinediones: effects on insulin resistance and the cardiovascular system.
@en
P2093
C J Lockhart
G E McVeigh
P K Hamilton
P2860
P304
P356
10.1038/SJ.BJP.0707452
P407
P577
2007-10-01T00:00:00Z